Real-World Effects of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol in Chinese Patients with Asthma

Background/Objectives: Asthma is a heterogeneous chronic inflammatory airway disease. In China, achieving rapid asthma control remains a major challenge, and a substantial proportion of patients remain inadequately controlled despite regular use of standard inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) therapy. Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) has demonstrated clinical efficacy in trials, but its real-world effectiveness and safety in China remain insufficiently characterized. This study evaluated FF/UMEC/VI (100/62.5/25 μg) in Chinese patients with uncontrolled asthma.